For Libraries For Publication Open Access Downloads About Us Contact Us
Paper Titles
The Formation of Plasma Acid at Atmospheric Pressure and its Application in Hydrolysis of Microcrystalline Cellulose
p.1626
Dynamic Self-Assembly Process of a Designed Peptide
p.1630
The Microstructure and Swelling Properties of Laminated HAp/CS Hydrogels
p.1635
A Modified Hydrothermal Synthesis and Luminescence of Hydroxyapatite Doped with Ce3+ and Tb3+ Ions
p.1639
PEG-PLGA Nanoparticle Modified by Transferrin Loading Doxorubicin: In Vitro and In Vivo Studies for Glioma
p.1643
The Primary Investigation on Biological Effect of Mesoporous Bioactive Glass In Vivo
p.1651
Cu Ion Release and Cell Damage Effect of Cu-Containing IUDs with Different Surface Areas of Copper
p.1656
Viscosity of Gelatin Solution Containing Cationic Crosslinker
p.1660
Decomposition of Hydroxyapatite in Hydroxyapatite/Zirconia Composites for Dental Applications
p.1664

PEG-PLGA Nanoparticle Modified by Transferrin Loading Doxorubicin: In Vitro and In Vivo Studies for Glioma

Article Preview

Abstract:

Purpose A biodegradable PEG-PLGA nanoparticle (NP) modified by transferrin (Tf) was conceived. Doxorubicin (Dox), a widely used antitumor agent, without passing through the BBB, which limited its utility on glioma, was encapsulated inside (Tf-NP-Dox). Furthermore, its therapeutic efficacy to glioma was evaluated both in vitro and in vivo. Methods Tf-NP-Dox was prepared via modified single emulsion method. Its characterization including size, Drug loading capacity (DLC), entrapment efficiency (EE), Tf number on Tf-NP-Dox surface were estimated. The antitumor efficiency in vitro was evaluated via MTT assay. The transmembrane transportation was evaluated via HPLC assay. The antitumor efficiency in vivo was assessed on C6 glioma intracranial implant rats model. Results The average diameter of Tf-NP-Dox is around 200 nm with surface Tf molecule number per Tf-NP-Dox approximately 25. MTT assay demonstrated stronger cytotoxicity of Tf-NP-Dox to C6 glioma cells (P<0.01). HPLC assay showed Tf-NP-Dox transport Dox into C6 with higher efficiency compare to NP-Dox or Dox (P<0.01). On C6 glioma bearing rat, Tf-NP-Dox could transport more Dox into tumors tested by HPLC assay (P<0.05), and extended life span markedly compared to NP-Dox or Dox (P<0.05). Conclusions Tf-NP-Dox had a potential of glioma targeting and had a better therapeutic effect to glioma both in vitro and in vivo.

You might also be interested in these eBooks
Advanced Engineering Materials III View Preview

Info:

Periodical:

Advanced Materials Research (Volumes 750-752)

Pages:

1643-1650

DOI:

https://doi.org/10.4028/www.scientific.net/AMR.750-752.1643

Citation:

Cite this paper

Online since:

August 2013

Authors:

Guo Dong Liu*, Jin Ning Mao, Tao Sun, Zhen Jiang, Jun Dong, Qiang Huang, Qing Lan

Keywords:

Biodegradable Nanoparticle, Chemotherapy, Doxorubicin, Glioma, Transferrin

Export:

RIS, BibTeX

Price:

Permissions CCC:

Request Permissions

Permissions PLS:

Request Permissions

Сopyright:

© 2013 Trans Tech Publications Ltd. All Rights Reserved

Share:

Citation:

* - Corresponding Author

References

[1] Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY: Lancet. Vol. 361(2003) No. 9354, p.323.

DOI: 10.1016/s0140-6736(03)12328-8

Google Scholar

[2] G. Caruso, M. Caffo, G. Raudino, C. Alafaci, FM. Salpietro, F. Tomasello: Recent Pat Nanotechnol. Vol. 5(2010) No. 1, p.53.

Google Scholar

[3] H. Ding, S. Inouea, A V. Ljubimov, R. Patila, J. Portilla-Ariasa, JW. Hua, B. Konda, KA. Wawrowsky, M. Fujita, N. Karabalin, T. Sasaki, KL. Black, E. Hollera and JY. Ljubimova: Proc Natl Acad Sci USA. Vol. 107(2010) No. 42, p.18143.

DOI: 10.1073/pnas.1003919107

Google Scholar

[4] N. Shah, K. Chaudhari, P. Dantuluri, R. S. R. Murthy, S. Das: Journal of Drug Targeting. Vol. 17(2009) No. 7, p.533.

Google Scholar

[5] Daniels TR, Delgado T, Helguera G, Penichet ML: Clin Immunol Vol. 121(2006) No. 2, p.159.

Google Scholar

[6] Y. Tsutsui, K. Tomizawa, M. Nagita, H. Michiue, T. Nishiki, I. Ohmori, M. Seno, HJ. Matsui: Control Release. Vol. 122(2007) No. 2, p.159.

DOI: 10.1016/j.jconrel.2007.06.019

Google Scholar

[7] Icci-Vitani, F. Pierconti, F. Malavasi, RD. Maria, U. Testa, and R. Pallini: Transl Oncol. Vol. 3(2010) No. 2, p.123.

Google Scholar

[8] Z. Qian, H. Li, H. Sun and K. Ho: Pharmacol. Rev. Vol. 54 (2002) No. 4, p.561.

Google Scholar

[9] JC. Olivier, R. Huertas, HJ. Lee, F. Calon, WM. Pardridge: Pharm Res. Vol. 19(2002) No. 8, p.1137.

Google Scholar

[10] Pan H, Han L, Chen W, Yao M, Lu W: J Control Release. Vol. 125(2008)No. 3, p.228.

Google Scholar

[11] Z. Pang, H. Gao, Y. Yu, L. Guo, J. Chen, S. Pan, J. Ren, Z. Wen and X. Jiang: Bioconjug Chem Vol. 22(2011)No. 6, p.1171.

Google Scholar

[12] Tian W, Ying X, Du J, Guo J, Men Y, Zhang Y, Li RJ, Yao HJ, Lou JN, Zhang LR, Lu WL: Eur J Pharm Sci Vol. 41(2010) No. 2, p.232.

Google Scholar

[13] J. Chang, A. Paillard, C. Passirani, M. Morille, JP. Benoit, D. Betbeder, E. Garcion: Pharm Res. Vol. 29(2012) No. 6, p.1495.

DOI: 10.1007/s11095-011-0624-1

Google Scholar

[14] P. Zhang, L. Hu, Q. Yin, L. Feng and Y. Li: Mol Pharm. Vol. 9(2012)No. 6, p.1590.

Google Scholar

[15] Liu Y, Lu WL, Guo J, Du J, Li T, Wu JW, Wang GL, Wang JC, Zhang X, Zhang Q: J Control Release. vol. 129 (2008) No. 1, p.18.

Google Scholar

[16] X. Ying, H. Wen, W. L. Lu, J. Du, J. Guo, W. Tian, Y. Men, Y. Zhang, R. J. Li, T. Y. Yang, D. W. Shang, J. N. Lou, L. R. Zhang and Q. Zhang: J. Control. Release. Vol. 141(2010) No. 2, p.183.

DOI: 10.1016/j.jconrel.2009.09.020

Google Scholar

[17] Prescott DM, Charles HC, Poulson JM, Page RL, Thrall DE, Vujaskovic Z, Dewhirst MW: Clin. Cancer Res. Vol. 6(2000)No. 6, p.2501.

Google Scholar

[18] Li Y, He H, Jia X, Lu WL, Lou J, Wei Y: Biomaterials. Vol. 33(2012) No . 15, p.3899.

Google Scholar

© 2025 Trans Tech Publications Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For open access content, terms of the Creative Commons licensing CC-BY are applied.
Scientific.Net is a registered trademark of Trans Tech Publications Ltd.